Aspartic peptidase inhibitors: Implications in drug development

Critical Reviews in Biochemistry and Molecular Biology

Volumn 38, Issue 2, 2003, Pages 89-119

  Dash, Chandravanu ^a   Kulkarni, Aarohi ^a   Dunn, Ben ^b   Rao, Mala ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Aspartic peptidases; Drugs; Inhibitors; Sequence homology

Indexed keywords

A 70450; AMINOPEPTIDASE; AMPRENAVIR; ASPARTIC PEPTIDASE; ASPARTIC PEPTIDASE INHIBITOR; ATAZANAVIR; BILA 2157BS; CARBOXYPEPTIDASE; CGP 38560; ENZYME INHIBITOR; INDINAVIR; LOPINAVIR; NELFINAVIR; OM 003; OM 992; PALINAVIR; PEPSIN A; PEPSTATIN; PEPTIDASE; PEPTIDE DERIVATIVE; PROTEINASE INHIBITOR; RENIN INHIBITOR; RITONAVIR; SAQUINAVIR; SC 5003; SIGNAL PEPTIDASE II; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; ZANKIREN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; BREAST CANCER; CANDIDIASIS; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HYPERTENSION; MALARIA; MEDICAL RESEARCH; METASTASIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; STOMACH ULCER; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0037727675     PISSN: 10409238     EISSN: None     Source Type: Journal    
DOI: 10.1080/713609213     Document Type: Review

References (179)

1. Abad-Zapatero, C., Goldman, R., Muchmore, S., Hutchins, C., Oie, T., Stewart, K., Cutfield, S., Cutfield, J., Foundling, S., and Ray, T. 1998. Structure of secreted aspartic proteinases from Candida - implications for the design of antifungal agents. Ad. Exp. Med. Biol. 436: 297-313.
2. Abad-Zapatero, C., Goldman, R., Muchmore, S., Hutchins, C., Stewart, K., Navaza, J., Payne, C., and Ray, T. 1996. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: Implications for the design of antifungal agents. Protein Sci. 5: 640-652.
3. Adkins, J. and Faulds, D. 1998. Amprenavir. Drugs 55: 837-842.
4. Asakura, T., Watanabe, H., Abe, K., and Arai, S. 1995. Rice aspartic proteinase, oryzasin, expressed during seed ripening and germination, has a gene organization distinct from those of animal and microbial aspartic proteinases. Eur. J Biochem. 232: 77-83.
5. Babine, R. and Bender, S. 1997. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 97: 1359-1472.
6. Baldwin, E., Bhat, T., Gulnik, S., Hosur, M., Sowder, R., Cachau, R., Collins, J., Silva, A., and Erickson, J. 1993. Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc. Natl. Acad. Sci. USA 90: 6796-6800.
7. Barett, A., Rawlings, N., and Woessner, J. 1998. In: Handbook of Proteolytic Enzymes Academic Press Inc., London.
8. Becker, M., Harrop, S., Dalton, J., Kalinna, B., McManus, D., and Brindley, P. 1995. Cloning and characterization of the Schistosoma japonicum aspartic proteinase involved in hemoglobin degradation. J. Biol. Chem. 270: 24496-24501.
9. Beckett, R., Davidson, A., Drummond, A., and Whittaker, M. 1996. Recent advances in matrix metalloproteinase inhibitor research. Drug Discov. Today 1: 16-26.
10. Bennett, B., Babu-Khan, S., Loeloff, R., Louis, J., Curran, E., Citron, M., and Vassar, R. 2000. Expression analysis of BACE2 in brain and peripheral tissues. J. Biol. Chem. 275: 20647-20651.
11. Bernstein, P., Edwards, P., and Williams, J. 1994. Inhibitors of human leukocyte elastase. Prog. Med. Chem. 31: 59-120.
12. Blundell, T., Cooper, J., Sali, A., and Zhu, Z. 1991. In: Structure and Function of the Aspartic Proteases. B. N. Dunn, Eds., pp. 443, Plenum Press, New York.
13. Bold, G., Fassler, A., Capraro, H., Cozens, R., Klimkait, T., Lazdins, J., Mestan, J., Poncioni, B., Rosel, J., Stover, D., Tintelnot-Blomley, M., Acemoglu, F., Beck, W., Boss, E., Eschbach, M., Hurlimann, T., Masso, E., Roussel, S., Ucci-Stoll, K., Wyss, D., and Lang, M. 1998. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 41: 3387-3401.
14. Brindley, P., Kalirma, B., Dalton, J., Day, S., Wong, J., Smythe, M., and McManus, D. 1997. Proteolytic degradation of host hemoglobin by schistosomas. Mol. Biochem. Parasitol. 89: 1-9.
15. Buhlmayer, P., Caselli, A., Fuhrer, W., Goschke, R., Rasetti, V., Rueger, H., Stanton, J., Criscione, L., and Wood, J. 1988. Synthesis and biological activity of some transition-state inhibitors of human renin. J. Med. Chem. 31: 1839-1846.
16. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D., Price, D., and Wong, P. 2001. BACE1 is the major β-secretase for generation of Ab peptides by neurons. Nature Neuroscience 4(3), 233-234 (English).
17. Carrillo, A., Stewart, K., Sham, H., et al. 1998. In vitro selection and characterization of human immunodeficiency virus type I variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72: 7532-7541.
18. Cassone, A., Bemardis, F., Torosantucci, A., Tacconelli, E., Tumbarello, M., and Cauda, R. 1999. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 180, 448-453.
19. Chatfield, D. and Brooks, B. 1995. HIV-1 protease cleavage mechanism elucidated with molecular-dynamics simulation. J. Am. Chem. Soc. 117: 5561-5572.
20. Chen, Z., Li, Y., Chen, E., Hall, D., Darke, P., Culberson, C., Schafer, J., and Kuo, L. 1994. Crystal structure at 1.9-Å resolution of human immunodeficiency virus (HIV) II protese complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J. Biol.Chem. 269: 26344-26348.
21. Christeller, J.T., Farley, P.C., Ramsay, R.J., Sullivan, P.A., and Laing, W.A. 1998. Purification, characterization and cloning of an aspartic proteinase inhibitor from squash phloem exudates. Eur. J. Biochem. 254: 160-167.
22. Coombs, G.H., Goldberg, D.E., Klemba, M., Berry, C., Kay, J., and Mottram, J.C. 2001. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trend Parasitol., 17 (11): 532-537.
23. Craik, M. and Debouck, C. 1995. In: Perspectives in Drug Discovery and Design, McKerrow, J. H. and James, M. N. G., Eds., ESCOM, Leiden, Vol. 2, pp. 1-125.
24. Cutfield, S., Dodson, E., Anderson, B., Moody, P., Marshall, C., Sullivan, P., and Cutfield, J. 1995. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure 3: 1261-1271.
25. D'Arcy-Lameta, A., Zuily-Fodil, Y., and Pham Thi, A. T., and Ferrari-Iliou, R. 1996. Vigna unguiculata aspartic proteinase mRNA. Complete cds, accession no. U61396.
26. Dales, N., Bohacek, R., Satyshur, K., and Rich, D. 2001. Design and synthesis of unsymmetrical peptidyl urea inhibitors of aspartic peptidases. Organic Letters 3, 2313-2316.
27. Dame, J., Reddy, G., Yowell, C., Dunn, B., Kay, J., and Berry, C. 1994. Sequence, expression and modeled structure of an aspartic proteinase from the human malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 64(2): 177-90 (English).
28. Darke, P. and Huff, J. 1994. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmacol. (San Diego), 25, 399-454 (English).
29. Dash, C., Phadtare, S., Deshpande, V., and Rao, M. 2001. Structural and mechanistic insight into the inhibition of aspartic proteases by a slow-tight binding inhibitor from an extremophilic Bacillus sp.: correlation of the kinetic parameters with the inhibitor induced conformational changes. J. Biol. Chem. 40: 11525-11532.
30. Dash, C., Vathipadiekal, V., George, S., and Rao, M. 2002, Slow-tight binding inhibition of xylanase by an aspartic protease inhibitor-kinetic parameters and conformational changes that determine the affinity and selectivity of the bifunctional nature of the inhibitor. J. Biol. Chem. 277: 17978-17986.
31. Dash, C. and Rao, M. 2001. Interactions of a novel inhibitor from an extremophilic Bacillus sp. with HIV-1 Protease: implications for the mechanism of inactivation. J. Biol. Chem. 276: 2487-2493.
32. De Bernardis, F., Arancia, S., Morelli, L., Hube, B., Sanglard, D., Schafer, W., and Cassone, A. 1999. Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J. Infect. Dis. 179: 201-208.
33. Doi, E., Shibata, D., Matoba, T., and Yonezawa, D. 1980. Characterization of pepstatin-sensitive acid protease in resting rice seeds. Agric. Biol. Chem. 44(4), 741-7 (English).
34. Dorsey, B., Levin, R., McDaniel, S., et al. 1994. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 37: 3443-3451.
35. Dunn, B. 1991. In: Structure and Function of the Aspartic Peptidases, Plenum Press, New York.
36. Dunn, B. 1992. In: Advances in Detailed Reaction Mechanisms, Coxon, J., Eds., Vol. 2, JA1 Press, Greenwich, Connecticut, pp. 213-241.
37. Dunn, B. 2002. Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem. Rev. 102: 4431-4458.
38. Dunn, B., Lewitt, M., and Pham, C. 1983. Inhibition of pepsin by analogs of pepsinogen-(1-12)-peptide with substitutions in the 4-7 sequence region. Biochem. J. 209(2): 355-62 (English).
39. Dunn, B., Scarborough, P., Lowther, W., and Rao-Naik, C. 1995. In: Aspartic Proteinases, Takahashi, K., Eds., Plenum Press, pp. 1-9.
40. Erickson, J. 1995. The not-so-great escape. Nat. Struct. Biol. 2(7), 523-9 (English).
41. Faro, C., Ramalho-Santos, M., Vieira, M., Mendes, A., Simões, I., Andrade, R., Veríssimo, P., Lin, X., Tang, J., and Pires, E. 1999. Cloning and characterization of cDNA encoding cardosin A, an RGD-containing plant aspartic proteinase. J. Biol. Chem. 274: 28724-28729.
42. Fath, M., Wu, X., Hileman, R., Linhardt, R., Kashem, M., Nelson, R., Wright, C., and Abraham, W. 1998. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J. Biol. Chem. 273: 13563-13569.
43. Fitzgerald, P., McKeever, B., VanMiddlesworth, J., Springer, J., Heimbach, J., Leu, C., Herber, W., Dixon, R., and Darke, P. 1990. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-Å resolution. J. Biol. Chem. 265: 14209-14219.
44. Francis, S., Gluzman, I., Oksman, A., Knickerbocker, A., Mueller, R., Bryant, M., Sherman, D., Russell, D., and Goldberg, D. 1994. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J. 13: 306-317.
45. Francis, S., Sullivan, D., Jr., and Goldberg, D. 1997. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. Rev. Microbiol., 51: 97-123 (English).
46. Frazão, C., Bento, I., Costa, J., Soares, C., Veríssimo, P., Faro, C., Pires, E., Cooper, J., and Carrondo, M. 1999. Crystal structure of cardosin A, a glycosylated and Arg-Gly-Asp-containing aspartic proteinase from the flowers of Cynara cardunculus L. J. Biol. Chem. 274: 27694-27701.
47. Fruton, J. 2002. A history of pepsin and related enzymes. Quart. Rev. Biol. 77(2): 127-147.
48. Fuetterer, J. and Hohn, T. 1987. Involvement of nucleocapsids in reverse transcription: a general phenomenon? Trends Biochem. Sci. (Pers. Ed.), 12(3), 92-5 (English).
49. Fung, H., Kirschenbaum, H., and Hameed, R. 2000. Amprenavir: a new human immunodeficiency virus type I protease inhibitor. Clin. Ther. 22: 549-572.
50. Fusek, et al. 1995. In: Aspartic Peptidases Physiology and Pathology, CRC Press, Boca Raton.
51. Garfinkel, D., Hedge, A., Youngren, S., and Copeland, T. 1991. Proteolytic processing of po1-TYB proteins from the yeast retrotransposon Ty1. Virology 65(9): 4573-81 (English).
52. Ghosh, A., Shin, D., Downs, D., Koelsch, G., Lin, X., Ermolieff, J., and Tang, J. 2000. Design of potent inhibitors for human brain memapsin 2 (b-secretase). J. Am. Chem. Soc. 122(14): 3522-3523 (English).
53. Gibson, W. and Hall, M. 1997. Assemblin, an essential herpesvirus proteinase. Drug Des. Discovery 15(1): 39-47 (English).
54. Girdwood, K., Perler, F.B., and Berry, C. 1998. Putative aspartic protease inhibitors from parasitic nematodes. In: Aspartic Proteinases: Retroviral and Cellular Enzymes: Advances in Experimental Medicine and Biology, Plenum Press, New York, pp. 419.
55. Glenner, G.C. and Wong, C.W. 1984. Alzheimer's disease: initial report of the purification and the characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890.
56. Goodenow, M., Bloom, G., Rose, S., Pomeroy, S., O'Brien, P., Perez, E., Sleasman, J., and Dunn, B. 2002. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type I (HIV-1) gag NC p7 and the C-cleavage site impact gagpol processing by HIV-1 protease. Virology 292: 137-149.
57. Goschke, R., Cohen, N., Wood, J., and Maibaum, J. 1997. Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin. Bioorg. Med. Chem. Lett. 7(21), 2735-2740 (English).
58. Gruber, A., Speth, C., Lukasser-Vogl, E., Zangerle, R., Borg-von Zepelin, M., Dierich, M., and Wurzner, R. 1999. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 41(3): 227-234 (English).
59. Guruprasad, K., Toermaekangas, K., Kervinen, J., and Blundell, T. 1994. Comparative modeling of barley-grain aspartic proteinase: a structural rationale for observed hydrolytic specificity. FEBS Lett. 352(2): 131-6 (English).
60. Heimgartner, U., Pietrzak, M., Geertsen, R., Brodelius, P., Figueiredo, A., and Pais, M. 1990. Purification and partial characterization of milk clotting proteases from flowers of Cynara cardunculus. Phytochemistry 29(5): 1405-10 (English).
61. Hellen, C. U. T. and Wimmer, E. 1992. The role of proteolytic processing in the morphogenesis of virus particles. Experientia. 48(2): 201-15 (English).
62. Hill, J. and Phylip, L. 1997. Bacterial aspartic proteinases. FEBS Lett. 409(3): 357-360 (English).
63. Hiraiwa, N., Kondo, M., Nishimura, M., and Hara-Nishimura, I. 1997. An aspartic endopeptidase is involved in the breakdown of propeptides of storage proteins in protein-storage vacuoles of plants. Eur. J. Biochem. 246: 133-141.
64. Holm, I., Ollo, R., Panthier, J., and Rougeon, F. 1984. Evolution of aspartyl proteases by gene duplication: the mouse renin gene is organized in two homologous clusters of four exons. EMBO J. 3: 557-562.
65. Hong, L., Turner, R. T., III, Koelsch, G., Shin, D., Ghosh, A. K., and Tang, J. 2002. Crystal structure of memapsin 2 (β-Secretase) in complex with an inhibitor OM00-3. Biochemistry. 41: 10963-10967.
66. Hoover, D., Lefker, B., Rosati, R., Wester, R., Kleinman, E., Bindra, J., Holt, W., Murphy, W., Mangiapane, M., et al. 1995. Discovery of inhibitors of human renin with high oral bioavailability. Adv. Exp. Med. Biol. 362(Aspartic Proteinases): 167-80 (English).
67. Howlett, D., Simmons, D., Dingwall, C., and Christie, G. 2000. In search of an enzyme: the β-secretase of Alzheimer's disease is an aspartic proteinase. Trend. Neurosci. 23: 565-570.
68. Hube, B., Sanglard, D., Odds, F., Hess, D., Monod, M., Schafer, W., Brown, A., and Gow, N. 1997. Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence. Infect. Immun. 65(9): 3529-3538 (English).
69. Hugli, T. 1996. Protease inhibitors: novel therapeutic application and development. Trend. Biotechnol. 14: 409-412.
70. Hurst, M. and Faulds, D. 2000. Lopinavir. Drugs 60: 1371-1379.
71. Hussain, I., Powell, D.J., Howlett, D.R., Chapman, G.A., Gilmour, L., Murdock, P.R., Tew, D.G., Meek, T.D., Chapman, C., Schneider, K., Ratcliffe, S.J., Tattersall, D., Testa, T.T., Southan, C., Ryan, D.M., Simmons, D.L., Walsh, F.S., Dingwall, C., and Christie, G. 2000. ASP1 (BACE2) cleaves the amyloid precursor protein at the β-secretase site. Mol. Cell. Neurosci. 16: 609-619.
72. Hussain, I., Powell, D., Howlett, D.R., Tew, D.G., Meek, T.D., Chapman, C., Gloger, I.S., Murphy, K.E., Southan, C.D., Ryan, D.M., Smith, T.S., Simmons, D.L., Walsh, F.S., Dingwall, C., and Christie, G. 1999. Identification of a novel aspartic protease (Asp2) as β-secretase. Mol. Cell. Neurosci. 14, 419-427.
73. Inoue, H., Kimura, T., Makabe, O., and Takahashi, K. 1991. The gene and deduced protein sequences of the zymogen of Aspergillus niger acid proteinase A. J. Biol. Chem. 266: 19484-19489.
74. Inouye, S., Yuki, S., and Saigo, K., 1986. Complete nucleotide sequence and genome organization of a Drosophila transposable genetic element, 297. Eur. J. Biochem. 154: 417-425.
75. James, M. 1998. In: Structure and Function of Aspartic Protease: Retroviral and Cellular Enzymes, Plenum Press, New York, pp. 1-481.
76. James, M. N. G., and Sielecki, A. R. 1987. In: Biological Macromolecules and Assemblies: Active Sites of Enzymes, Jurnak, F. A. and McPherson, A., Eds., John Wiley & Sons, New York. Vol. 3, p. 413.
77. James, M. and Sielecki, A. 1987. Aspartic proteases and their catalytic pathway inhibitors. In: Biological Macromolecules and Assemblies: Active Sites of Enzymes, Jumak, F. and McPhersin, A., Eds., John Wiley & Sons, New York, pp. 413.
78. Johns, M., Babcock, M., Fuerstenberg, S., Fuerstenberg, S., Freeling, M., and Simpson, R. 1989. An unusually compact retrotransposon in maize. Plant Mol. Biol. 12(6), 633-42 (English).
79. Johnson, L., Dyer, R., and Hupe, D. 1998. Matrix metalloproteinases. Curr. Opin. Chem. Biol. 379: 113-123.
80. Kageyama, T. 1998. Molecular cloning, expression and characterization of an Ascaris inhibitor for pepsin and cathepsin E. Eur. J. Biochem. 253: 804-809.
81. Kaldor, S., Kalish, V., Davies, J., et al. 1997. Viracept (nelfinavir mesylate, AG1343): potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40: 3979-3985.
82. Kay, J. 1985. In: Aspartic Proteases and Their Inhibitors, Kostka, V., Ed. Walter de Gruyter, Berlin, pp. 1-17.
83. Kay, J., Valler, M. J., and Dunn, B. N. 1983. In: Protease Inhibitors Medical and Biological Aspects, Katunuma, N., Umezawa, H., and Holzer, H., Eds., Japan Scientific Societies Press, Tokyo, pp. 201-210.
84. Kempf, D. and Sham, H. 1996. HIV protease inhibitors. Curr. Pharm. Des. 2(2): 225-246 (English).
85. Kempf, D., Marsh, K., Kumar, G., Rodrigues, A., Denissen, J., McDonald, E., Kukulka, M., Hsu, A., Granneman, G., Baroldi, P., Sun, E., Pizzuti, D., Platmer, J., Norbeck, D., and Leonard, J. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency vires protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41(3): 654-660 (English).
86. Kervinen, J., Lubkowski, J., Zdanov, A., Bhatt, D., Dunn, B., Hui, K., Powell, D., Kay, J., Wlodawer, A., and Gustchina, A. 1998. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1,FIV, and EIAV. Prot. Sci., 7:2314-2323.
87. Kervinen, J., Tobin, G., Costa, J., Waugh, D., Wlodawer, A., and Zdanov, A. 1999. Crystal structure of plant aspartic proteinase prophytepsin: inactivation and vacuolar targeting. EMBO J. 18: 3947-3955.
88. Kim, E., Baker, C., Dwyer, M., Murcko, M. Rao, B., Tung, R., and Navia, M. 1995. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117: 1181-1182.
89. Kim, J., Morgenstern, K., Lin, C., Fox, T., Dwyer, M., Landro, J., Chambers, S., Markland, W., Lepre, C., et al. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell (Cambridge, MA.), 87(2): 343-355 (English).
90. Kleinert, H., Stein, H., Boyd, S., Fung, A., Baker, W., Verburg, K., Polakowski, J., Kovar, P., Barlow, J., et al. 1992. Discovery of a well-absorbed, efficacious renin inhibitor, A-74273. Hypertension (Dallas) 20(6): 768-75 (English).
91. Kreft, S., Ravnikar, M., Mesko, P., Pungercar, J., Umek, A., Kregar, I., and Strukelj, B. 1997. Jasmonic acid inducible aspartic proteinase inhibitors from potato. Phytochemistry 44(6), 1001-1006 (English).
92. Lacy, M. and Abriola, K. 1996. Indinavir: a pharmacologic and clinical review of a new HIV protease inhibitor. Conn. Med. 60: 723-727.
93. Lam, P., Jadhav, P., Eyermarm, C., et al. 1994. Rational design of potent, bioiavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263: 380-384.
94. Lamarre, D., Croteau, G., Wardrop, E., Bourgon, L., Thibeault, D., Clouette, C., Vaillancourt, M., Cohen, E., Pargellis, C., Yoakim, C., and Anderson, P. 1997. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 41(5): 965-971 (English).
95. Lea, A. and Faulds, D. 1996. Ritonavir. Drugs 52(4): 541-546 (English).
96. Lenarcic, B. and Turk, V. 1999. Thyroglobulin Type-1 domains in equistatin inhibit both papain-like cysteine proteinases and cathepsin D. J. Biol. Chem. 274: 563-566.
97. Li, M., Phylip, L., Lees, W., Winther J., Dunn, B., Wlodawer, A., Kay, J., and Gustchina, A. 2000. The aspartic proteinase from Saccharomyces cerevisiae folds its own inhibitor into a helix. Natur. Struc. Biol. 7(2): 113-117.
98. Li, Z., Chen, X., Davidson, E., Zwang, O., Mendis, C., Ring, C., Roush, W., Fegley, G., Li, R., et al. 1994. Anti-malarial drug development using models of enzyme structure. Chem. Biol. 1(1): 31-7 (English).
99. Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A., and Tang, J. 2000. Human aspartic protease memapsin 2 cleaves the -secretase site of -amyloid precursor protein. Proc. Natl. Acad. Sci. USA 97: 1456-1460.
100. Love, R., Parge, H., Wickersham, J., Hostomsky, Z., Habuka, N., Moomaw, E., Adachi, T., and Hostomska, Z. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell (Cambridge, Mass.), 87(2): 331-342 (English).
101. Luo, Y., Bolon, B., Kahn, S., Bennett, B., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., Martin, L., Louis, J., Yan, Q., Richards, W., Citron, M., and Vassar, R. 2001. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nature Neurosci. 4(3): 231-232 (English).
102. MacKay, V., Welch, S., Insley, M., Manney, T., Holly, J., Saari, G., and Parker, M. 1988. The Saccharomyces cerevisiae BAR1 gene encodes an exported protein with homology to pepsin. Proc. Natl. Acad. Sci. USA, 85(1): 55-9 (English).
103. Majer, P., Collins, J., Gulnik, S., and Erickson, J. 1997. Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors. Protein Sci. 6: 1458-1466.
104. Masters, C.L., Simms, G., Weidemann, N.A., Multhaup, G., McDonald, B.L., and Beyreuther, K. 1985. Amyloid plaque core protein in Alzheimer's disease and Down's Syndrome. Proc. Natl. Acad. Sci. USA 82: 4245-4249.
105. Menon, A. and Goldberg, A. 1987. Protein substrates activate the ATP-dependent protease La by promoting nucleotide binding and release of bound ADP. J. Biol. Chem. 262: 14929-14934.
106. Miller, M., Jaskolski, M., Rao, J., Leis, J., and Wlodawer, A. 1989. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature (London), 337(6207): 576-9 (English).
107. Monod, M., Hube, B., Hess, D., and Sanglard, D. 1998. Differential regulation of SAP8 and SAP9, which encode two new members of the secreted aspartic proteinase family in Candida albicans. Microbiology 144: 2731-2737.
108. Mutlu, A., Pfeil, J., and Gal, S. 1998. A probarley lectin processing enzyme purified from Arabidopsis thaliana seeds. Phytochemistry 47(8): 1453-1459 (English).
109. Naglik, J., Newport, G., White, T., Fernandes-Naglik, L., Greenspan, J., Greenspan, D., Sweet, S., Challacombe, S., and Agabian, N. 1999. In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis. Infect. Immun. 67(5): 2482-2490 (English).
110. Nezami, A., Luque, I., Kimura, T., Kiso, Y., and Freire, E. 2002. Identification and characterization of allophenylnorstatine-based inhibitors of plasmapepsin II, an antimalarial tartget. Biochemistry 41: 2273-2280.
111. Ng, K.K.S., Peterson, J., Cherney, M., Garen, C., Zalatoris, J., Rao-Naik, C., Dunn, B., Martzen, M., Peanasky, R., and James, M. 2000. Structural basis for the inhibition of porcine pepsin by Ascaris pepsin inhibitor-3. Natur. Struct. Biol. 7 (8): 653-657.
112. Noble, S. and Goa, K. 2000. Amprenavir: a review of its clinical potential in patients with HIV infection. Drugs 60:1383-1410.
113. Northrop, D. 2001. Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Accounts Chem. Res.. 34(10): 790-797.
114. Oda, K., Takahashi, T., Tokuda, Y., Shibano, Y., and Takahashi, S. 1994. Cloning, nucleotide sequence, and expression of an isovaleryl pepstatin-insensitive carboxyl proteinase gene from Pseudomonas sp. 101. J. Biol. Chem. 269, 26518-26524.
115. Oefner, C., Binggeli, A., Breu, V., Bur, D., Clozel, J-P., D'Arcy, A., Dorn, A., Fischli, W., Grüninger, F. Güller, R., Hirth, G., Märki, H.P., Mathews, S., Müller, M., Ridley, R.G., Stadler, H., Vieira, E., Wilhelm, M., Winkler, F.K., and Wostl, W., 1999. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? Chem. Biol. 6, 127-131.
116. Pakyz, A. and Israel, D. 1997. Overview of protease inhibitors. J. Am. Pharm. Assoc. (Washington) NS37: 543-551.
117. Papassotiropoulos, A., Bagli, M., Feder, O., Jessen, F., Maier, W., Rao, M., Ludwig, M., Schwab, S., and Heun, R. 1999. Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's Disease. Neurosci. Lett. 262: 171-174 (English).
118. Patick, A. and Potts, K. 1998. Protease inhibitors as antiviral agents. Clin. Microbiol. Rev. 11: 614-627.
119. 3 inhibitor and its target aspartic proteinase from Saccharomyces cerevisiae. J. Biol. Chem. 276: 2023-2030.
120. Powell M., Holdsworth R., Baker T., Titmas R., Bose C., Phipps A., Eaton, M., Rolph, C. E., Valler, M. J., and Kay, J. 1984. In: Aspartic Proteases and Their Inhibitors. pp. 479-483.
121. Ramalho-Santos, M., Verissimo, P., Cortes, L., Samyn, B., Van Beeumen, J., Pires, E., and Faro, C. 1998. Identification and proteolytic processing of procardosin A. Eur. J. Biochem. 255: 133-138.
122. Rao, M., et al. 1998. Molecular and biotechnological aspects of microbial proteases. Microbiol. Mol. Biol. Rev. 62(3): 597-635.
123. Rao-Naik, C., Guruprasad, K., Batley, B., Rapundalo, S., Hill, J., Blundell, T., Kay, J., and Dunn, B. 1995. Exploring the binding preferences/specificity in the active site of human cathepsin E. Proteins: Struct. Funct. Genet. 22(2): 168-81 (English).
124. Reid, W. A., Vongsorasak, L., Svasti, J., Valler, M. J., and Kay. 1984. Identification of the acid proteinase in human seminal fluid as a gastricsin originating in the prostate. J. Cell Tissue Res. 236(3): 597-600 (English).
125. Rich, D. 1985. Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transitionstate analog inhibitor. J. Med. Chem. 28(3): 263-73 (English).
126. Ripka, A., Satyshur, K., Bohacek, R., and Rich, D. 2001. Aspartic protease inhibitors designed from computer-generated templates bind as predicted. Organic Letters 3: 2309-2312.
127. Roberts, N., Martin, J., Kinchington, D., et al. 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248: 358-361.
128. Rochefort, H. and Liaudet-Coopman, E. 1999. Cathepsin D in cancer metastasis: a protease and a ligand. APMIS 107(1): 86-95 (English).
129. Rosenberg, S. H. 1995. Renin inhibitors. In: Progress in Medicinal Chemistry. Ellis, G. P. and Loscombe, D. K., Eds., Elsevier Science, New York, Vol. 32, pp. 37-115.
130. Runeberg-Roos, P., Kervinen, J., Kovaleva, V., Raikhel, N., and Gal, S. 1994. Aspartic proteinase of barley is a vacuolar enzyme that processes probarley lectin in vitro. Plant Physiol. 105(1): 321-9 (English).
131. Runeberg-Roos, P., Tormakangas, K., and Ostman, A. 1991. Primary structure of a barley-grain aspartic proteinase. A plant aspartic proteinase resembling mammalian cathepsin D. Eur. J. Biochem. 202: 1021-1027.
132. Rusconi, S., La Seta, C., Citterio, P., et al. 2000. Susceptibility to PNU-140690 (Tiprinavir) of human immunodeficiency virus type I isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents. Chemother. 44: 1328-1332.
133. Rutenber, E., Fauman, E., Keenan, R., Fong, S., Furth, P., Montellano, P., Meng, E., Kuntz, I., DeCamp, D., Salto, R., Rose, J., Craik, C., and Stroud, R. 1993. Structure of a non-peptide inhibitor complexed with HIV-1 protease. J. Biol. Chem. 268: 15343-15346.
134. Saftig, P., Hetman, M., Schmahl, W., Weber, K., Heine, L., Mossmann, H., Koster, A., Hess, B., Evers, M., and Von Figura, K. 1995. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 14: 3599-3608.
135. Sanglard, D., Hube, B., Monod, M. Odds, F., and Gow, N. 1997. A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence. Infect. Immun. 65: 3539-3546.
136. Sarkkinen, P., Kalkkinen, N., Tilgmann, C., Siuro, J., Kervinen, J., and Mikola, L. 1992. Aspartic proteinase from barley grains is related to mammalian lysosomal cathepsin D. Planta 186(3): 317-23 (English).
137. Seife, C. 1997. Blunting nature's Swiss army knife [news]. Science 277: 1602-1603.
138. Semenov, A., Olson, J., and Rosenthal, P. 1998. Anti-malarial synergy of cysteine and aspartic protease inhibitors. Antimicrob. Agents Chemother. 42(9): 2254-2258 (English).
139. Sham, H., Kempf, D., Molla, A., et al. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42: 3218-3224.
140. Shaw, E. 1990. Cysteinyl proteinases and their selective inactivation. Adv. Enzymol. Relat. Areas Mol. Biol. 63: 271-347.
141. Shetty, B., Kosa, M., Khalil, D., and Webber, S. 1996. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40: 110-114.
142. Shieh, S., Kurumbail, R., Stevens, A., Stegeman, R., Sturman, E., Pak, J., Witwer, A., Palmier, M., Weigand, R., Holwerda, B., and Stallings, W. 1996. Three-dimensional structure of human cytomegalovirus protease. Nature 383: 279-282.
143. Sielecki, R., Fujinanga, M., Read, R. J., and James, M. N. G. 1991. Refined structure of porcine pepsinogen at 1.8 Å resolution. J. Mol. Biol. 219: 671-692.
144. Silva, A. M., Lee, A. Y., Gulnik, S. V., Maier, P., Collins, J., Bhat, T. N., Collins, P. J., Cachau, R. E., Luker, K. E., Gluzman, I. Y., Francis, S. E., Oksman, A., Goldberg, D. E., and Erickson, J. 1996. Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 93, 10034-10039.
145. Simoneau, B., Lavallee, P., Anderson, P. C., Bailey, M., Bantle, G., Berthiaume, S., Chabot, C., Fazal, G., Halmos, T., Ogilvie, W. W., Poupart, M. A., Thavonekham, B., Xin, Z., Thibeault, D., Bolger, G., Panzenbeck, M., Winquist, R., and Jung, G. L. 1999. Discovery of non-peptidic P2-P3 butanediamide renin inhibitors with high oral efficacy. Bioorg. Med. Chem. 7: 489-508.
146. Skrbec, D. and Romeo, D. 2002. Inhibition of Candida albicans secreted aspartic protease by a novel series of peptidomimetics, also active on the HIV-1 protease. Biochem. Biophys. Res. Commun. 297, 1350-1353.
147. Song, M., Rajesh, S., Hayashi, Y., and Kiso, Y. 2001. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. Bioorg. Med. Chem. Lett. 11, 2465-2468.
148. Stragier, P., Bonamy, C., and Karmazyn-Campelli, C. 1988. Processing of a sporulation sigma factor in Bacillus subtilis: how morphological structure could control gene expression. Cell 52: 697-704.
149. Stubbs, M. T. and Bode, W. 1993. A player of many parts: the spotlight falls on thrombin's structure. Thromb. Res. 69, 1-53.
150. Symersky, J., Monod, M., and Foundling, S. I. 1997. High-resolution structure of the extracellular aspartic proteinase from Candida tropicalis yeast. Biochemistry 36: 12700-12710.
151. Szelke, M., Leckie, B., Hallet, A., Jones, D. M., Sueiras, J., Atrash, B., and Lever, A. F. 1982. Potent new inhibitors of human renin. Nature 299: 555-557.
152. Takahashi, K. 1995. In: Aspartic Peptidases Structure. Function, Biology and Biomedical Implications, Plenum Press, New York.
153. Takahasi, K. 1995. In: Function, Biology, and Biomedical Implications, Plenum Press, New York and London.
154. Tanaka, R. D., Clark, J. M., Warne, R. L., Abraham, W. M., and Moore, W. R. 1995. Mast cell tryptase: a new target for therapeutic intervention in asthma. Int. Arch. Allergy Immunol. 107: 408-409.
155. Tanaka, R., Clark, J., Warne, R., Abraham, W., and Moore, W. 1995. Mast cell tryptase: a new target for therapeutic intervention in asthma. Int. Arch. Allergy Immunol. 107: 408-409.
156. Tang, J. 1977. In: Acid Proteases, Structure, Function, and Biology, New York, Plenum Press.
157. Tang, J. 1979. Evolution in the structure and function of carboxyl proteases. Mol. Cell Biochem. 26: 93-109.
158. Thaisrivongs, S. and Strobach, J. 1999. Structure-based discovery of Tiprinavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 51: 51-58.
159. Thompson, P., Higgins, D., and Gibson, T. 1994. Clustal W: improving sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucelic Acids. Res. 22: 4673-4680.
160. Tone, H., Matsushita, Y., Yagi, Y., and Tamamatsu, A. 1975. Purification and properties of pepstatin hydrolase from Bacillus sphaericus. J. Antibiot. 28: 1012-1015.
161. Torruella, M., Gordon, K., and Hohn. T. 1989. Cauliflower mosaic virus produces an aspartic proteinase to cleave its polyproteins. EMBO J. 8: 2819-2825.
162. Turner, R.T., III, Koelsch, G., Hong, L., Castenheira, P., Ghosh, A., and Tang, J. 2001. Subsite specificity of Memapsin 2 (b-Secretase): implications for inhibitor design. Biochemistry 40(34): 10001-10006 (English).
163. Turner, S., Strohbach, J., Tommasi, R., et al. 1998. Tiprinavir (PNU-140690): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 41: 3467-3476.
164. Umezawa, H., Ayogi, T., Morishima, H., Matsuzaki, M., Hamada, M., and Takeuchi, T. 1970. Pepstatin, a new pepsin inhibitor produced by Actinomycetes. J. Antibiot. 23: 259-262.
165. Vacca, J., Dorsey, B., Schleif, W., et al. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type I protease inhibitor. Proc. Natl. Acad. Sci. USA 91: 4096-4100.
166. Vassar, R., Bennet, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, B. D., Ross, S., Amarante, P., Leoloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jaronsinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J.-C., Collins, F., Treanor, J., Roger, G., and Citron, M. 1999. Betasecretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741.
167. Veerapandian, B., Cooper, J., Sali, A., Blundell, T., Rosati, R., Dominy, B., Damon, D., and Hoover, D. 1992. Direct observation by X-ray analysis of the tetrahedral "intermediate" of aspartic proteinases. Protein Sci. 1(3): 322-328.
168. Verissimo, P., Faro, C., Moir, AJ., Lin, Y., Tang, J., and Pires, E. 1996. Purification, characterization and partial amino acid sequencing of two new aspartic proteinases from fresh flowers of Cynara cardunculus L. Eur. J. Biochem. 235: 762-768.
169. Wacher, V. J., Silverman, J. A., Zhang, Y., and Bennett, L. Z. 1998. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87: 1322-30.
170. West, M. L. and Fairlei, D. P. 1995. Targeting HIV-1 protease: a test of drug-design methodologies. Trend. Pharmacol. Sci. 16: 67-75.
171. White, P., Cordeiro, M., Arnold, D., Brodelius, P., and Kay, J. 1999. Processing, activity, and inhibition of recombinant cyprosin, an aspartic proteinase from cardoon (Cynara cardunculus). J. Biol. Chem. 274, 16685-16693.
172. Wilimowska-Pelc, A., Polanowski, A., Kolaczkowska, M. K., Wieczorek, M., and Wilusz, T. 1983. Preparation and characteristics of trypsin inhibitors from the seedsof squash (Cucurbita maxima) and zucchini (Cucurbita pepo var, Giromontia). Acta Biochim. Pol. 30, 23-31.
173. Wlodawer A, 2002. Rational approach to AIDS drug design through structural biology. Annu. Rev. Med. 53: 595-614.
174. Wlodawer, A. and Erickson, J. W. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62: 543-585.
175. Wolfe, M. S., Xia, W., Moore, C. L., Leatherwood, D. D., Ostaszewski, B., Rahmati, T., Donker, I. O., and Selkoe, D. J. 1999. Peptidomimetic probes and molecular modeling suggest that alzheimer's-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry 38: 4720-4727.
176. Yan, S., Sameni, M., and Sloane, B. F. 1998. Tumor cell membrane cathepsin B. Biol. Chem. 379: 113-23.
177. Yoshioka, K., Honma, H., Zushi, M., Kondo, S., Togashi, S., Miyake, T., and Shiba, T. 1990. Virus-like particle formation of Drosophila copia through autocatalytic processing. EMBO J. 9: 535-541.
178. Yuasa, Y., Shimojo, H., Ayogi, T., and Umezawa, H. 1975. Effect of protease inhibitors on focus formation by murine sarcoma virus. J. Natl. Cancer Inst. 54: 1255-1256.
179. Zhang, Z., ElSohly, H., Jacob, M., Pasco, D., Walker, L., and Clark, A. 2002. Natural products inhibiting Candida albicans secreted aspartic proteases from Lycopodium cernuum. J. Natural Prod. 65: 979-985.